Johnson & Johnson Submits Application to U.S. FDA Seeking Approval of Tremfya® (Guselkumab) for the Treatment of Moderately to Severely Active Crohn's Disease
強生公司向美國FDA提交申請,尋求批准Tremfya®(Guselkumab)用於治療中度至重度活動性克羅恩病。
Johnson & Johnson Submits Application to U.S. FDA Seeking Approval of Tremfya® (Guselkumab) for the Treatment of Moderately to Severely Active Crohn's Disease
強生公司向美國FDA提交申請,尋求批准Tremfya®(Guselkumab)用於治療中度至重度活動性克羅恩病。
譯文內容由第三人軟體翻譯。